ADVENTRX Pharmaceuticals Submits ANX-530 New Drug Application

Monday, January 4, 2010 Drug News
Email Print This Page Comment
Font : A-A+

Company Contact:

ADVENTRX Pharmaceuticals

Brian Culley, Principal Executive Officer

858-552-0866

Investor Contact:

Lippert/Heilshorn & Associates, Inc.

Don Markley (dmarkley@lhai.com)

310-691-7100



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Advertisement
Advertisement

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook